Active, not recruitingPhase 3NCT04213261
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa
Studying Dystrophic epidermolysis bullosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Castle Creek Biosciences, LLC.
- Intervention
- FCX-007 (dabocemagene autoficel; see below for FCX-007 description)(biological)
- Enrollment
- 6 enrolled
- Eligibility
- 2 years · All sexes
- Timeline
- 2020 – 2037
Study locations (5)
- Stanford University, Stanford, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Solutions Through Advanced Research, Inc., Jacksonville, Florida, United States
- Mayo Clinic, Rochester, Minnesota, United States
- Dell Children's Medical Group, Austin, Texas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04213261 on ClinicalTrials.govOther trials for Dystrophic epidermolysis bullosa
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06594393A Phase 2 Study of TCP-25 Gel in Patients With Epidermolysis Bullosa, STEP-studyXinnate AB
- RECRUITINGPHASE1, PHASE2NCT07193134GMEB-SASS: A Gene-Modified Skin Substitute for RDEB TreatmentCHU de Quebec-Universite Laval
- RECRUITINGPHASE1, PHASE2NCT06834035Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis BullosaM. Peter Marinkovich
- RECRUITINGPHASE3NCT07016750A Study Comparing KB803 and Matched Placebo in Patients With Dystrophic Epidermolysis BullosaKrystal Biotech, Inc.
- RECRUITINGPHASE3NCT06917690A Study to Learn About the Safety and Efficacy of the Drug Oleogel-S10 in Japanese Patients With Epidermolysis BullosaChiesi Farmaceutici S.p.A.
- ACTIVE NOT RECRUITINGPHASE3NCT06892639Evaluation of D-Fi for the Treatment of Wounds Due to DEBCastle Creek Biosciences, LLC.
- RECRUITINGNCT06423573A Study to Assess the Incidence of Skin Cancers in Patients With Epidermolysis Bullosa Receiving FilsuvezAmryt Pharma
- RECRUITINGPHASE1, PHASE2NCT04173650MSC EVs in Dystrophic Epidermolysis BullosaAegle Therapeutics